TY - JOUR
T1 - Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol
T2 - A valuable tool for evaluating progressive supranuclear palsy
AU - Weng, Ruihui
AU - Wei, Xiaobo
AU - Yu, Bin
AU - Zhu, Shuzhen
AU - Yang, Xiaohua
AU - Xie, Fen
AU - Zhang, Mahui
AU - Jiang, Ying
AU - Feng, Zhong Ping
AU - Sun, Hong Shuo
AU - Xia, Ying
AU - Jin, Kunlin
AU - Chan, Piu
AU - Wang, Qing
AU - Gao, Xiaoya
N1 - Funding Information:
This work was supported by the National Key R&D Program of China (NO: 2017YFC1310200 ), National Natural Science Foundation of China (Grant NO: 81471291 ), Science and Technology Program of Guangdong of China (NO: 2016A050502019 ), Natural Science Foundations of Guangdong of China (NO: 2014A020212068 , 2017A030311010 ), Leading Talent in Talents Project-Guangdong High-level Personnel of Special Support Program , and Scientific Research Foundation of Guangzhou (NO: 2014J4100210 , 201704030080 ) to Q.W; and Natural Science Foundations of Guangdong of China (NO: 2017A030313672 ) to SZZ; and National Science Foundation of Guangdong Province (NO: 2015A030313859 ), Science and Technology Program of Guangdong of China (NO: 2016A020215204 ), and Science and Technology Program of Guangzhou of China (NO: 201607010126 ) to XYG.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/7
Y1 - 2018/7
N2 - Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.
AB - Introduction: Progressive supranuclear palsy (PSP) was previously thought as a cause of atypical Parkinsonism. Although Cystatin C (Cys C) and low-density cholesterol lipoprotein-C (LDL-C) are known to play critical roles in Parkinsonism, it is unknown whether they can be used as markers to distinguish PSP patients from healthy subjects and to determine disease severity. Methods: We conducted a cross-sectional study to determine plasma Cys C/HDL/LDL-C levels of 40 patients with PSP and 40 healthy age-matched controls. An extended battery of motor and neuropsychological tests, including the PSP-Rating Scale (PSPRS), the Non-Motor Symptoms Scale (NMSS), Geriatric Depression Scale (GDS) and Mini-Mental State Examination (MMSE), was used to evaluate the disease severity. Receiver operating characteristic (ROC) curves were adopted to assess the prognostic accuracy of Cys C/LDL-C levels in distinguishing PSP from healthy subjects. Results: Patients with PSP exhibited significantly higher plasma levels of Cys C and lower LDL-C. The levels of plasma Cys C were positively and inversely correlated with the PSPRS/NMSS and MMSE scores, respectively. The LDL-C/HDL-C ratio was positively associated with PSPRS/NMSS and GDS scores. The ROC curve for the combination of Cys C and LDL-C yielded a better accuracy for distinguishing PSP from healthy subjects than the separate curves for each parameter. Conclusions: Plasma Cys C and LDL-C may be valuable screening tools for differentiating PSP from healthy subjects; while they could be useful for the PSP intensifies and severity evaluation. A better understanding of Cys C and LDL-C may yield insights into the pathogenesis of PSP.
KW - Cystatin C
KW - Low-density lipoprotein cholesterol
KW - Neurocognitive disorder
KW - Progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85044281313&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2018.03.014
DO - 10.1016/j.parkreldis.2018.03.014
M3 - Article
C2 - 29574085
AN - SCOPUS:85044281313
SN - 1353-8020
VL - 52
SP - 37
EP - 42
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -